Biogen/Idec: still a matter of size

Biogen/Idec: still a matter of size
The merger of Biogen and Idec Pharmaceuticals, announced June 23, is likely to help the two relatively isolated companies increase presence in their disease areas. The annual R&D budget for the new pharmaceutical entity, to be called Biogen Idec Inc, will be $500 million, according to company reports.

Comments are closed.

Do NOT follow this link or you will be banned from the site!
Get email updates

Get new actionable insights and updates from BiotechBlog